- Home
- SCWO vs XBIT Comparison
SCWO vs XBIT Comparison
Compare SCWO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | XBIT |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Environmental Services | Pharmaceuticals and Biotechnology |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 71.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SCWO | XBIT |
|---|---|---|
| Price | $2.77 | $2.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.4K | 26.8K |
| Earning Date | 04-02-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $2.09 |
| 52 Week High | $3.55 | $3.62 |
Technical Indicators
Market Signals| Indicator | SCWO | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 54.01 |
| Support Level | $2.35 | $2.32 |
| Resistance Level | $3.10 | $2.49 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 74.73 | 75.94 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.